Alnylam pharmaceuticals reports fourth quarter and full year 2021 financial results and highlights recent period activity

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended december 31, 2021 and reviewed recent business highlights. “2021 was another remarkable year at alnylam, in which we delivered significant product revenue growth of 83% compared to 2020, achieving results at the upper end of our combined product sales guidance range driven by strong pa
ALNY Ratings Summary
ALNY Quant Ranking